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Abstract
Background: There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. 
Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe 
psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, 
respectively. 
Methods: This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe 
psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been 
evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or 
dermatology life quality index (DLQI) ≤5), estimated from the societal perspective over a 6-months duration. All costs 
are based on 2015’s recorded Malaysian Ringgit (RM) currency. 
Results: Consequently, TS has been found to be the most cost-effective treatment with the lowest cost/PASI-75/and/or 
BSA <5 and/or DLQI ≤5, valued at RM9034.56 (US$2582.55). This is followed by TP, which is valued at RM28 080.71 
(US$8026.93) and TB, valued at RM54 287.02 (US$15 518.06). Furthermore, one-way sensitivity analysis has highlighted 
the cost of medication as the most sensitive parameter. 
Conclusion: Thus, the input from this study is helpful for policy-makers in determining the first line treatment for 
moderate to severe psoriasis with consideration of the costs and its effectiveness in Malaysia. This will consequently 
allow hospitals to justify and provide the essential resources for further research and development, as well as the adoption 
of better treatment options.
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Implications for policy makers
• Determination of the most cost-effective strategy for the moderate to severe psoriasis patients in Malaysia.
• Topical and biologic (TB) intervention exhibited highest total cost which was RM434 296.15 (US$124 144.50).
• Topical and systemic (TS) treatment was the most cost effectiveness treatment with the lowest cost per  psoriasis area severity index (PASI)-75 
and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5 which was RM9034.56 (US$2582.55).
• TS appeared to the most cost-effective treatment in the situation where majority of the patients were moderate psoriasis (PASI >10-20, BSA 
>10-30 and DQLI >10-20).
• The findings will help policy makers in allocation of the resources for the betterment of the psoriasis management in Malaysia.
Implications for the public
This is the first study conducted in Malaysia to measure cost, effectiveness and cost effectiveness of 3 psoriasis interventions namely; topical 
and phototherapy (TP), topical and systemic (TS), topical and biologic (TB). TP modality was associated with highest loss of productivity cost, 
RM152 940.00 (US$43 718.23) or 59% of the total productivity costs. TS incurred highest monitoring costs, which was RM37 676.40 (US$10 769.88) or 
69% of the total lab tests cost. Meanwhile, TB yielded greatest cost of medication, RM410 118.87 (US$117 233.38) or 67% of the total medication cost. 
In terms of effectiveness, TB showed the highest (66.7%) while TS appeared to be the most cost-effective treatment with RM9,034.56 (US$2582.55)/
psoriasis area severity index (PASI)-75 and/or body surface area (BSA) <5 and/or dermatology life quality index (DLQI) ≤5. The findings of this study 
will help policy-makers in determining appropriate resource allocation for psoriasis management in Malaysia as well as adoption of better strategy 
considering cost and effectiveness.
Key Messages 
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Background 
Psoriasis is a skin disease characterized by a dry and thick 
silvery scaling on its surface. Occurring worldwide, it 
affects 7.5 million Americans equivalent to 2% to 4% of its 
population,1 2.8% of the UK population,2 0.19% to 0.24% 
in Taiwan, and 0.4% in China.3 In Malaysia specifically, a 
total of 17 071 patients with psoriasis from 24 dermatology 
centres (20 government hospitals, 2 private centres and 2 
university hospitals) were registered in Malaysia Psoriasis 
Registry during the period of 2007 until 2016.4 For a majority 
of the cases, it typically begins at the age of 20-35 years old 
and synonymous with a paramount effect upon the quality 
of one’s life, comparable to other chronic diseases like cancer, 
hypertension, heart disease and diabetes.5,6 Psoriasis is also 
associated with various comorbidities, such as non-alcoholic 
fatty liver disease (ie, the most prevalent comorbidity in 
western countries),7 obesity, hypertension, dyslipidaemia and 
diabetes,8,9 and mental illness.10 
Therefore, various treatment regimens have been outlined 
for cases of moderate to severe psoriasis, which includes 
phototherapy, systemic and biologic methods. In many 
cases, topical agents are generally used as co-medications to 
reduce the side effects and enhance the effectiveness of the 
treatments. Then, phototherapy utilises UV light to absorb 
into the skin and reduce cell proliferation, and induce T 
cells and keratinocyte apoptosis.11,12 Meanwhile, systemic 
medications are prescription drugs that affect the entire body 
and given to patients who are nonresponsive to phototherapy.6 
These systemic agents and its usage should be decided with 
consideration of their dosage, safety and side effects.13,14 In 
contrast to systemic treatment, biologic treatment functions 
by reducing symptoms of the disease by targeting a specific 
immune pathway. Commonly considered as the best 
discovery in the management of moderate to severe psoriasis, 
most biologic agents have demonstrated high safety profiles 
without causing toxicity in the organs.15,16 These agents are 
widely used in Spain, with 19.4% of the total psoriasis patients 
being prescribed with it, followed by the United Kingdom 
(9.1%), and France (8.4%).17 However, the number of patients 
receiving this type of treatment is still limited in Malaysia. 
The different treatment modalities are distinguishable due 
to their significant effects on the overall cost. Despite being 
highly efficacious, biologic therapy is particularly attributable 
to sizable incremental costs, thus resulting in a considerable 
financial impact.18,19 For systemic treatment, the overall cost 
of the treatment is increased by the need for screening and 
monitoring tests to be done prior so as to identify any risks of 
toxicity developing. Meanwhile, phototherapy is particularly 
limiting as it causes significant loss of productivity due to 
patients who may have to take off days to get their treatment 
at the outpatient clinic, amounting to twice or 3 times a week. 
An estimated 15%-20% of patients have reported to experience 
reduced of working ability,20-23 whereas a staggering 49% of 
them have missed their working days due to psoriasis.24
Given the considerable economic impact of psoriasis 
towards patients and hospitals alike, this has rendered an 
economic analysis comparing the cost-effectiveness of these 
treatment modalities to be imperative. However, most of the 
available studies are reported to be either of low quality and 
short time duration, using non-comparable effectiveness 
measures, recorded incomplete cost calculation, or lacks a 
sensitivity analysis.25 Moreover, differences in methodological 
criteria for the studies have also yielded inconclusive findings. 
To date, no study has yet attempted to measure the cost-
effectiveness of psoriasis treatment modalities in this region. 
Thus, the objective of this study is to evaluate the cost-
effectiveness of 3 psoriasis treatment modalities from the 
societal perspective, namely: topical and phototherapy (TP), 
topical and systemic (TS), topical and biologic (TB).
Methods
Design and Setting
A prospective cohort study has been conducted in 5 public 
hospitals (ie, Universiti Kebangsaan Malaysia Medical Centre, 
Hospital Kuala Lumpur, Hospital Pulau Pinang, Hospital 
Sultanah Bahiyah, and Hospital Sultanah Aminah) involving 
a total of 90 psoriasis patients between January 2016 until 
March 2017. 
The inclusion criteria were moderate to severe psoriasis 
(psoriasis area severity index [PASI] >10 and/or body 
surface area [BSA] >10 and/or dermatology life quality index 
[DLQI] >10), which was similar to the local and international 
guideline for the management of psoriasis vulgaris,4,26,27,55 
sought treatment (TP, TS, and TB) at the study settings 
between January 2016 until August 2016, aged 18 years and 
above and Malaysian citizenship. The choice of treatment was 
made based on clinical criteria, without randomization. Mild 
psoriasis patients were excluded. 
Measure of Effectiveness 
Effectiveness was measured based on the PASI, BSA, and 
DLQI scores. The specific indicator of effectiveness was PASI-
75 (75% improvement over the baseline score) and/or BSA 
<5 (affected area has reduced) and/or DLQI ≤5 (disease has 
minimal impact on quality of life), 6 months after treatment 
is initiated. 
Cost Analysis 
An economic evaluation was conducted to calculate costs 
associated with the management of moderate to severe 
psoriasis, effectiveness and cost-effectiveness of all 3 
modalities over a period of 6-months. Discounting for future 
costs and results was not applied in cost analysis because both 
cost and effective outcomes occurred at the same period of 
time (maximum of 6 months).12 The total costs of managing 
moderate to severe psoriasis were calculated from societal’s 
perspective. All costs were presented in Malaysian Ringgit 
(RM) 2015. From provider’s perspective, cost of medication, 
lab tests and radiology were included. Meanwhile, patient’s 
costs include out-of-pocket expenses and transportation 
(direct cost) and loss of productivity (indirect cost). Loss of 
productivity was measured using human capital approach 
(calculated as; daily income/number of days of patients were 
unable to work). Medication cost was calculated based on the 
unit price of drug year 2015 and this information was obtained 
from the hospital’s administrative. Cost of phototherapy, lab 
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tests and radiological procedure were estimated using the 
Ministry of Health’s Fee Act 1951 (revised 1982) for Ministry 
of Health hospitals (Hospital Kuala Lumpur, Hospital Pulau 
Pinang, Hospital Sultanah Bahiyah, and Hospital Sultanah 
Aminah)28 and charges posed by Universiti Kebangsaan 
Malaysia Medical Centre. Details of medication, lab tests 
and radiology were explained in the previous study.29 All 
were added to provide total cost of medication. Patient 
costing form provided primary data for patient out-of-pocket 
expenditures, transportation and time taken off work, for a 
duration of 6 month after being recruited into the study. The 
cost effectiveness was measured by the cost per PASI-75 and/
or BSA <5 and/or DLQI ≤5 achieved. This was calculated by 
dividing the total cost by the number of patients who achieved 
this response. Then, a sensitivity analysis has been conducted 
to resolve any uncertainties behind the input parameters, by 
integrating variability in the results and producing confidence 
intervals for each strategy. This has been done to determine 
and evaluate the robustness of the outcomes towards variations 
in the final decision model. A scenario analysis based on 3 
cases (ie, best, base, and worst case) has also been constructed 
by applying a 15% variation into both critical variable, cost 
and effectiveness (into average cost and effectiveness) and 
this was similar to the previous study done by Vañó-Galván et 
al.11 One-way analysis has also been conducted by applying ± 
15% on every variable in the study such as cost of medication 
(ie, systemic, biologic), cost of lab tests and radiology, loss 
of productivity, probability of effectiveness (PASI-75 and/or 
BSA <5 and/or DLQI ≤5), cost of transportation and out-of-
pocket expenses to determine the most sensitive parameter 
the model. Statistical analysis was performed using version 
21.0 of the Statistical Package for Social Sciences (SPSS Inc.) 
and Microsoft Excel 2010 for the cost analysis. 
Results 
A total of 90 moderate to severe psoriasis patients were 
included in the study. The demographic characteristics 
of the respondents are shown in Table 1. Majority of the 
respondents were male, 60 (66.7%), mean age was 45 ± 15 
years old (range 19-84 years), 57 (53.3%), Malays, 56 (62.2%), 
have low educational background, 54 (60%), married, 60 
(67.7%), employed, 49 (54.4%), having monthly income more 
than RM3000, 61 (67.8% and have mean ± standard deviation 
(SD) baseline PASI, BSA, and DLQI 16.02 ± 10.54, BSA 
26.66 ± 21.72 and 13.87 ± 5.72 respectively. With respect to 
comorbidity, majority of them have hypertension, 45 (33.3%) 
(Figure 1).
Table 2 presents the total costs associated with psoriasis 
treatments over a 6-month period. TB has been found 
Table 1. Demographic Profile of the Respondents (n = 90)
Characteristics No. (%)
Gender
Male 60 (66.7)
Female 30 (33.3)
Mean age ± SD 45 ± 15 (range 19-84)
Ethnicity
Malays 56 (62.2)
Non-Malays 34 (8.8)
Education
Low (no schooling, primary school, 
secondary school) 54 (60.0)
High (college/university) 36 (40.0)
Marital status
Single 30 (33.3)
Married 60 (66.7)
Occupation 
Unemployed 35 (38.9)
Self-employed 6 (6.7)
Employed 49 (54.4)
Income 
RM 0-3000 29 (32.2)
RM >3000 61 (67.8)
Mean PASI baseline score 16.02±10.54
Mean BSA baseline score 26.66±21.72
Mean DLQI baseline score 13.87±5.72
Abbreviations: SD, standard deviation; RM, Malaysian Ringgit; PASI, psoriasis 
area severity index; BSA, body surface area; DLQI, dermatology life quality 
index.
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Figure 1. Comorbidity Among Patients.
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to produce the highest total cost, value at RM434 296.15 
(RM36 191.35/patient), followed by TS, valued at 
RM298 140.44 (RM4969.01/patient), and TP, valued at 
RM224 645.68 (RM12 480.32/patient) (Table 2). Figure 2 
demonstrates cost according to the components for each 
modality. TB treatment has produced highest total cost 
of medication which was RM410 118.87 (RM34 176.57/
patient), TS has generated highest total cost of lab tests and 
transportation which was RM37 676.40 (RM627.94/patient) 
and RM7160.00 (RM119.33), respectively. Meanwhile, TP 
treatment has yielded greatest loss of productivity cost which 
was RM152 940.00 (RM8496.67/patient). The result also 
indicates that there was statistically significant difference 
in cost of medication, lab tests, transportation and loss of 
productivity among 3 types of treatment options (Table 3).
Next, Figure 3 illustrates the effectiveness of the treatments 
which was measured by the number of patients achieved 
PASI-75 and/or BSA <5 and/or DLQI ≤5. TB treatment has 
the highest number of patients achieved PASI-75 and/or BSA 
<5 and/or DLQI ≤5 which was 8 out of 12 patients (67.7%), 
followed by TS with 33 out of 60 patients (55.0%) and TP with 
8 out of 18 patients (44.4%).
Table 4 shows the base-case results of the cost-effectiveness 
analysis from the societal perspective over a 6-month period. 
TS has been revealed as the most cost-effective modality as 
it yields the lowest cost per PASI-75 and/or BSA <5 and/
or DLQI ≤5, valued at RM9034.56. This is followed by 
TP treatment, which is valued RM28 080.71, and finally, 
TB treatment, valued at RM54,287.02. The incremental 
cost effectiveness ratio (ICER) of TS compared to TP was 
RM2939.79 per additional patient with a PASI-75 and/or BSA 
<5 and/or DLQI ≤5 (calculated as follows; [RM298 140.44-
RM224 645.68]/[33 patients with a PASI-75 and/or BSA <5 
and/or DLQI ≤5, -8 patients with a PASI-75 and/or BSA <5 
and/or DLQI ≤5]), whereas TB was dominated by TS with as 
denoted by negative ICER which was -RM5446.23 (calculated 
as follows: [RM434 296.15-RM298 140.44]/[8 patients with a 
PASI-75 and/or BSA <5 and/or DLQI ≤5–33 patients with a 
PASI-75 and/or BSA <5 and/or DLQI ≤5]).
Then, a scenario analysis (as per Table 5) was undertaken 
Table 2. Overall Costs Associated With the Management of Moderate to Severe 
Psoriasis
Treatment Total cost (RM) Cost/Patient (RM) Percent P Value
TP (n = 18) 224 645.68 12 480.32 23.5 .001
TS (n = 60) 298 140.44 4969.01 31.2 .001
TB (n = 12) 434 296.15 36 191.35 45.4 .001
Total (n = 90) 957 082.27 10 634.25
Abbreviations: TP, topical and phototherapy; TS, topical and systemic; TB, 
topical and biologic; RM, Malaysian Ringgit.
Figure 2. Costs From Patient’s Perspective According to Treatment. 
Abbreviations: TP, topical and phototherapy; TS, topical and systemic; TB, 
topical and biologic.
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Table 3. Mean Cost According to the Components
Input 
Treatment
P ValueTP (n = 18) TS (n = 60) TB (n = 12)
Mean (SD) Mean (SD) Mean (SD)
Provider
Medicationa 2994.45 (1541.21) 2482.74 (2389.72) 34 176.57 (8809.28) .00
Lab testsa 387.53 (312.90) 627.94 (291.30) 824.86 (466.85) .00
Radiology 5.56 (RM16.70) 23.33 (41.65) 24.50 (22.92) .164
Total mean cost (RM) 3387.54 3134.01 35 025.93
Patient
Out of pocket expenses 366.67 (810.41) 108.75 (254.65) RM190.00 (401.50) .09
Transportationa 229.44 (215.58) 119.33 (110.74) 169.17 (123.27) .00
Loss of productivitya 8496.67 (7626.14) 1606.91 (4954.32) 806.25 (616.22) .00
Total mean cost (RM) 9092.78 1834.99 1165.42 .00
Total costs  (RM) 224 645.76 298 140.44 434 296.15 .001
Abbreviations: SD, standard deviation; RM, Malaysian Ringgit; TP, topical and phototherapy; TS, topical and systemic; TB, topical and biologic.
a ANOVA, significant at P < .05.
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with a 15% variation of cost and effectiveness, with the cost 
per PASI-75 and/or BSA <5 and/or DLQI ≤5 for TP regiment 
valued at RM9079.43 in the best-case scenario (mean cost 
reduced by a 15% and an effective response [50% (9/18)]), 
RM28 080.71 in the base case, (mean cost and effective 
response [44% (8/18)]) and RM36 906.08 in the worst case 
(mean cost increased by a 15% and effective response [39% 
(7/18)]). Meanwhile, the cost per PASI-75 and/or BSA <5 and/
or DLQI ≤5 for TS in the best case was RM6668.93 (mean cost 
reduced by a 15% and effectiveness response [63% (38/60)]), 
RM9038.69 in the base case (mean cost and effective response 
[53% (32/60)]) and RM12 245.05 in worst case (mean cost 
increased by a 15% and effective response [47% (28/60)]). 
Kos per PASI-75 and/or BSA <5 and/or DLQI ≤5 for TB was 
RM41 016.86 in the best case (mean cost reduced by a 15% 
and effective response [75% (9/12)]), RM54 287.02 in the base 
case (average cost and effective response [67% (8/12)]) and 
RM71 348.65 in the worst care (mean cost increased by a 15% 
Figure 3. Effectiveness of the Treatment Modalities. 
Note: Effectiveness = percentage or number of patients achieved PASI-75 and/
or BSA <5 and/or DLQI ≤5.  Abbreviations: TP, topical and phototherapy; TS, 
topical and systemic; TB, topical and biologic.
Table 4. Base-Case Result of the Cost-Effectiveness
Treatment Total Cost (RM) Effectivenessa (%) (n) Cost-Effectivenessb ICER
TP 224 645.68 44.4 (8/18) 28 080.71 -
TS 298 140.44 55.0 (32/60) 9034.56 2939.79
TB 434 296.15 67.7 (8/12) 54 287.02 -5446.23
Abbreviations: TP, topical and phototherapy; TS, topical and systemic; TB, topical and biologic; RM, Malaysian Ringgit; ICER, incremental cost effectiveness ratio.
a Effectiveness  (%) = percentage of patients achieved PASI-75 and/or BSA <5 and/or DLQI ≤5.
b Cost effectiveness = total cost divides by the number of patients achieved PASI-75 and/or BSA <5 and/or DLQI ≤5.
Table 5. Scenario Analysis
Treatment
Scenario (Cost-Effectiveness) (RM)
Besta Baseb Worstc 
TP 21 216.54 28 080.71 36 906.08
TS 6668.93 9034.56 12 245.05
TB 41 016.86 54 287.02 71 348.65
Abbreviations: TP, topical and phototherapy; TS, topical and systemic; TB, 
topical and biologic; RM, Malaysian Ringgit.
a Best case = average cost reduced to 15% and effectiveness response 
increased to 15%.
b Base case = average cost and effectiveness response.
c Worst case = average cost increased to 15% and effectiveness response 
reduced to 15%.
and effective response [58% (7/12)]).
Figure 4A-B illustrates a Tornado diagram expressed 
in ICER. Dotted lines correspond to the ICER value in the 
base-case scenario. One-way sensitivity analysis pointed out 
the cost of biologics and loss of productivity cost as the most 
sensitive parameter of the model. 
Discussion 
This study has emerged as the first and pioneering 
economic evaluation in assessing the cost-effectiveness of 
3 psoriasis treatments for moderate to severe psoriasis in 
Malaysia. Previous analyses of the cost-effectiveness of these 
interventions has yielded mixed results. Some evidence has 
suggested the biologic modality as the most cost-efficient 
option compared to other modalities.30-32 Meanwhile, other 
works have indicated that the systemic treatment has generated 
the lowest cost per PASI response33 whereas several studies 
have demonstrated phototherapy to be the most cost-effective 
regiment. Nevertheless, this particular work has suggested the 
TS treatment to be the most cost-effective modality, despite 
TB showing the best results in terms of effectiveness. This 
especially relevant as the cost-effectiveness analysis taking 
into account both cost and effectiveness in determining the 
most cost-effective strategy. The costs analysis in this study 
has demonstrated that the total cost of TS to be twice lesser 
than TB, whereas effectiveness difference has only been found 
to be at 13%. Hence, this indicates that the TS treatment 
modality is the most cost-effective regimen. 
The inconsistent findings obtained in determining the most 
cost-effective treatment for moderate to severe psoriasis can 
be attributed to several factors. One of them includes different 
effectiveness measure, which is believed to be the main cause 
for the large variation in cost-effectiveness values displayed in 
this study versus Sizto et al.35 The latter work has found that 
systemic medication (eg, cyclosporine) has exhibited the lowest 
cost/quality-adjusted life year from the societal perspective in 
the United Kingdom, valued at RM165 441.90 (£25 135). This 
is in comparison with the biologic regiment, which is valued 
between RM245 408.27 to RM279 688 (£37 284-£42 492). In 
this particular study, the cost/PASI-75 and/or BSA <5 and/or 
DLQI ≤5 for systemic treatment has also been found to be less 
than the biologic treatment, valued at RM9038.69 compared 
to RM52 659.51 respectively. Furthermore, the duration of 
time taken for the study to be undertaken is also capable of 
influencing the results. Pearce et al36 have demonstrated the 
systemic agent to be the most cost-effective strategy in the 
United States, with the lowest cost/PASI-75 of RM2837.62 
(US$623). However, that value is particularly less compared to 
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this study that has yielded a value of RM9038.69 (US$2583.73). 
The previous study has calculated cost and effectiveness for a 
systemic agent during a 12-week time period, as opposed to 
this study that has measured four systemic medications (ie, 
methotrexate, cyclosporine, acitretin and sulphasalazine) for 
24 weeks. Therefore, a longer duration is capable of affecting 
the outcome, as both overall costs and the probability of 
treatment success are both increased. This is also justified 
by the work by Cabello Zurita et al37 whereby approximately 
33.3% of the patients being treated with methotrexate have 
achieved 75% reduction of psoriasis symptoms by week 12. 
The percentage has shown considerable increments to 34.9%, 
44.7%, and 52.8% at week 16, 24, and 48 respectively. 
The duration of the cost effectiveness study of the psoriasis 
treatment modalities defined in different works is also 
variable. Knight et al38 have assessed cost-effectiveness of 
psoriasis treatments for 10 years, Verma et al39 at 5 years, 
Villacorta et al40 at 3 years, Küster et al30 at 2 years, Ahn et 
al,41 and Salazar et al42 at 1 year. The time of horizon of less 
than 1 year was sustained by available evidence. Although 
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Figure 4. (A) Tornado Diagram Expressed in Terms of ICER Impact (TS vs. TP). (B) Tornado Diagram Expressed in Terms of ICER Impact (TB vs. TS).
Abbreviations: TS, topical and systemic; TP, topical and phototherapy; TB, topical and biologic; RM, Malaysian Ringgit; ICER, incremental cost effectiveness ratio; BSA, 
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a long-time horizon is preferred, data associated with to 
the long-term experience with several psoriasis therapies is 
still lacking. Such information includes the annual drop-out 
rates from treatment, the ‘remission’ period, the efficacy of 
subsequent lines of treatment, the cost and incidence of side 
effects and the risk of hospitalization.43 
Furthermore, numerous studies focused on the economic 
evaluation of psoriasis treatments have typically compared 
2 interventions only.11,32,44-46 Out of the 19 studies that have 
differentiated the cost-effectiveness of disparate treatment 
options, only few studies have opted to evaluate in terms of 3 
interventions, namely systemic, biologic and phototherapy.32-36 
Most of the recent analyses are generally dominated by studies 
evaluating the cost-effectiveness of biologic drugs.40,43,47-51 
This evaluation is especially relevant as the biologic regiment 
is commonly known as the best intervention in treating 
moderate to severe psoriasis, offering high safety profile, 
fewer side effects and increased patient’s quality of life. Hence, 
a cost-effectiveness study is paramount to justify the need for 
biologic agents in the respective countries.
In this study, PASI-75 and/or BSA <5 and/or DLQI ≤5 has 
been considered as an outcome. These responses are widely 
used in studies involving psoriasis, with PASI, in particular, 
being underlined as the gold standard and meeting the 
criteria of methodological validity.26,27,52,53 Furthermore, the 
score has also been proven to be strongly correlated with 
BSA and DLQI.56,57 Previous studies have opted for utility 
measures, whereby the clinical outcome is converted to 
utility score using the EuroQol 5-dimensional questionnaire. 
Then, it is used to estimate the quality-adjusted life year. 
However, various evidence has demonstrated that PASI 
and DLQI responses to range between weak to moderately 
correlated with EuroQol 5-dimensional questionnaire.58,59 
Hence, using utility values by means of PASI response has 
been linked to a high level of bias.54 Additionally, another 
important information elicited from the findings of this study 
is that the cost of medication (ie, biologic and systemic) is the 
most sensitive parameters. Similarly, various previous works 
have highlighted the biologic medications as the highest 
contributor towards the overall cost of medication,54 resulting 
in several-fold escalation of overall cost of treatments.19,54,60 
Similarly, analytical trends in systemic psoriasis treatment 
costs have revealed that biologic medications to exceed 
general inflation, with an incremental rate for biologic agents 
of 120% for etanercept, 103% for adalimumab and 53% for 
ustekinumab during the period 2004-2014. In contrast, their 
average annual increment within the same period is 8.2% 
for etanercept, followed by 9.2% (adalimumab) and 11.0% 
(ustekinumab).61 
Regardless, this study is also associated with several 
limitations. Firstly, the respondents have been recruited 
from 5 tertiary, government-run hospitals only and excluded 
patients who sought treatment in private clinics and hospitals. 
Hence, the data obtained may not be completely representative 
of all cases of moderate to severe psoriasis in Malaysia. 
Nevertheless, it has provided meaningful insight to clinicians 
anyway regarding resource utilization in managing psoriasis. 
Secondly, time duration utilised in this study is less than a 
year despite psoriasis being a long-term and chronic disease. 
Therefore, is important to establish a cost-effectiveness model 
that is capable of predicting changes and interruptions during 
treatment, as well as its effectiveness in many coming years. 
But, conducting and maintaining a long-term study is a very 
difficult task due to the high dropout rate and mid-treatment 
changes occurring. It is justifiable that high drop out rate could 
lead to selection bias that affects conclusion of the finding. 
Therefore, the findings of the study could be limited to the 
fact that TS is the most cost-effective treatment in Malaysia if 
majority of the patients are moderate psoriasis (PASI >10-20, 
BSA >10-30 and DLQI >10-20 as refers to the classification 
of disease severity by the guideline of the Management of 
Psoriasis Vulgaris in Malaysia).6 Thirdly, the associated side 
effect costs have also been excluded. Generally, the side 
effects of a treatment are very complex, especially for diseases 
involving many comorbidities like psoriasis. This renders 
costing calculations to be a demanding and challenging task, 
despite the inevitable importance of the role that side effects 
play during treatment decision-making. 
Conclusion
Treatment for moderate to severe psoriasis causes considerable 
direct and indirect costs. TB treatment exhibited highest 
effectiveness but, TS treatment is considered the most cost-
effective strategy in Malaysia situation in where majority of 
the patients are moderate psoriasis. The important finding of 
this study is to guide policy makers to determine the first line 
treatment considering its cost and effectiveness for moderate 
to severe psoriasis in Malaysia, allows hospitals to justify 
and provide the essential capitals for further research and 
development as well as adoption of better treatment options. 
Future cost-effective analysis should provide information on 
the long-term experience with psoriasis interventions and 
manage the uncertainty associated with key drivers of the cost 
effectiveness of psoriasis treatments.
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